MA55491A - Anticorps anti-pyroglutamate-amyloïde bêta et leurs utilisations - Google Patents

Anticorps anti-pyroglutamate-amyloïde bêta et leurs utilisations

Info

Publication number
MA55491A
MA55491A MA055491A MA55491A MA55491A MA 55491 A MA55491 A MA 55491A MA 055491 A MA055491 A MA 055491A MA 55491 A MA55491 A MA 55491A MA 55491 A MA55491 A MA 55491A
Authority
MA
Morocco
Prior art keywords
pyroglutamate
amyloid beta
beta antibodies
antibodies
amyloid
Prior art date
Application number
MA055491A
Other languages
English (en)
Inventor
Wilson Edwards
Rajkumar Ganesan
Chichi Huang
Porte Sherry La
Jinquan Luo
Marc Mercken
Sanjaya Singh
Broeck Bianca Van
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA55491A publication Critical patent/MA55491A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA055491A 2019-03-26 2020-03-25 Anticorps anti-pyroglutamate-amyloïde bêta et leurs utilisations MA55491A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962823785P 2019-03-26 2019-03-26

Publications (1)

Publication Number Publication Date
MA55491A true MA55491A (fr) 2022-02-09

Family

ID=70008544

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055491A MA55491A (fr) 2019-03-26 2020-03-25 Anticorps anti-pyroglutamate-amyloïde bêta et leurs utilisations

Country Status (22)

Country Link
US (4) US11236155B2 (fr)
EP (1) EP3946603A1 (fr)
JP (2) JP7617848B2 (fr)
KR (1) KR20210143858A (fr)
CN (2) CN120468431A (fr)
AU (1) AU2020245031A1 (fr)
BR (1) BR112021019107A2 (fr)
CA (1) CA3134785A1 (fr)
CL (2) CL2021002473A1 (fr)
CO (1) CO2021014028A2 (fr)
CR (1) CR20210492A (fr)
DO (1) DOP2021000199A (fr)
EA (1) EA202192606A1 (fr)
EC (1) ECSP21079184A (fr)
IL (1) IL286634A (fr)
JO (1) JOP20210265A1 (fr)
MA (1) MA55491A (fr)
MX (1) MX2021011715A (fr)
PE (1) PE20212266A1 (fr)
PH (1) PH12021552334A1 (fr)
SG (1) SG11202110504XA (fr)
WO (1) WO2020193644A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
WO2020193644A1 (fr) * 2019-03-26 2020-10-01 Janssen Pharmaceutica Nv Anticorps anti-pyroglutamate-amyloïde bêta et leurs utilisations
JP2023528797A (ja) 2020-05-26 2023-07-06 トゥルーバインディング，インコーポレイテッド ガレクチン－３を遮断することにより炎症性疾患を処置する方法
MX2023000949A (es) 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).
TW202334200A (zh) * 2021-10-28 2023-09-01 美商艾伯維有限公司 抗澱粉樣蛋白β抗體及其使用方法
AU2023232448A1 (en) * 2022-03-11 2024-10-24 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof
AU2023230027A1 (en) 2022-03-11 2024-10-24 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof
AU2023232447A1 (en) * 2022-03-11 2024-10-24 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof
IL321331A (en) 2022-12-22 2025-08-01 Bioarctic Ab Antibody that binds to ABETAPE3
US20250388664A1 (en) 2024-06-20 2025-12-25 Bioarctic Ab Bispecific binding molecule
CN118459582B (zh) * 2024-07-11 2024-11-15 苏州近岸蛋白质科技股份有限公司 一种抗焦谷氨酸修饰的β淀粉样蛋白抗体及其用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
US5642870A (en) 1992-08-05 1997-07-01 Sargis; Ike Switch stand
US5761894A (en) 1996-09-25 1998-06-09 Magic Circle Corporation Grass striping attachment for lawn mowers
US9907485B2 (en) 2004-10-15 2018-03-06 Brainlab Ag Targeted immunization and plaque destruction against Alzheimer's disease
US7625560B2 (en) * 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US20110182809A1 (en) 2008-07-09 2011-07-28 University Of Zurich Method of Promoting Neurogenesis
NZ590563A (en) 2008-07-21 2012-06-29 Probiodrug Ag Diagnostic antibody assay
ES2624835T3 (es) 2009-08-06 2017-07-17 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
CA2787657A1 (fr) * 2010-02-23 2011-09-01 Genentech, Inc. Compositions et methodes pour le diagnostic et le traitement d'une tumeur
WO2011151076A2 (fr) 2010-06-04 2011-12-08 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Anticorps monoclonaux ciblant des oligomères aβ
WO2012021475A2 (fr) 2010-08-12 2012-02-16 Eli Lilly And Company ANTICORPS CONTRE LE PEPTIDE N3pGLU AMYLOÏDE BÊTA ET LEURS UTILISATIONS
LT3339323T (lt) 2010-08-12 2020-02-10 Eli Lilly And Company Amiloido beta peptido antikūnai prieš n3glu ir jų panaudojimas
EP2511296A1 (fr) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Anticorps, kit et procédé pour déterminer des peptides amyloïdes
ITRM20120383A1 (it) 2012-03-20 2013-09-21 Uni Degli Studi Di Milano B Icocca Metodo e kit per la rivelazione di anticorpi.
WO2015175769A1 (fr) 2014-05-15 2015-11-19 Biogen Ma Inc. Procédés de détection d'oligomères bêta-amyloïdes dans des échantillons biologiques
WO2015191825A1 (fr) 2014-06-13 2015-12-17 Biogen Ma Inc. Méthodes pour la détection et la mesure de la protéine beta amyloïde dans des échantillons biologiques
PT3177642T (pt) * 2014-08-07 2022-02-14 Novartis Ag Anticorpos semelhantes a angiopoietina 4 e métodos de uso
JP2018501482A (ja) 2014-12-19 2018-01-18 プロビオドルグ エージー ｐＧｌｕ−Ａｂｅｔａペプチドの検出のための新規の方法
JP7002811B2 (ja) * 2015-07-16 2022-03-04 ビボリョン セラピューティクス エヌブイ 抗ピログルタミン酸化アミロイドβヒト化抗体
JOP20170004B1 (ar) * 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TW201740954A (zh) 2016-03-16 2017-12-01 美國禮來大藥廠 組合療法
EP3249388A1 (fr) 2016-05-23 2017-11-29 Raman Health Technologies, S.L Procédé de diagnostic de la maladie d'alzheimer
MX2018015022A (es) 2016-06-07 2019-08-14 Biogen Int Neuroscience Gmbh Métodos para el tratamiento de la enfermedad de alzheimer.
CA3032692A1 (fr) 2016-08-09 2018-02-15 Eli Lilly And Company Polytherapie a base d'anticorps pour le traitement de maladies neurodegeneratives
TWI669119B (zh) 2016-10-21 2019-08-21 美國禮來大藥廠 組合療法
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
JOP20190247A1 (ar) 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
BR112019022906A2 (pt) * 2017-05-02 2020-05-26 Prothena Biosciences Limited Anticorpos que reconhecem tau
EP4233901A3 (fr) 2017-08-22 2023-09-06 Biogen MA Inc. Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
WO2020069372A1 (fr) * 2018-09-27 2020-04-02 Elstar Therapeutics, Inc. Molécules multispécifiques csf1r/ccr2
WO2020193644A1 (fr) * 2019-03-26 2020-10-01 Janssen Pharmaceutica Nv Anticorps anti-pyroglutamate-amyloïde bêta et leurs utilisations

Also Published As

Publication number Publication date
DOP2021000199A (es) 2022-07-15
US20220106387A1 (en) 2022-04-07
ECSP21079184A (es) 2021-11-30
JP2025000645A (ja) 2025-01-07
BR112021019107A2 (pt) 2021-11-30
PE20212266A1 (es) 2021-11-30
CL2022002670A1 (es) 2023-03-31
KR20210143858A (ko) 2021-11-29
CN120468431A (zh) 2025-08-12
CA3134785A1 (fr) 2020-10-01
US11236155B2 (en) 2022-02-01
JP7617848B2 (ja) 2025-01-20
JOP20210265A1 (ar) 2023-01-30
EA202192606A1 (ru) 2022-01-24
CL2021002473A1 (es) 2022-04-22
EP3946603A1 (fr) 2022-02-09
WO2020193644A1 (fr) 2020-10-01
MX2021011715A (es) 2021-12-10
CN113891746A (zh) 2022-01-04
JP2022526528A (ja) 2022-05-25
IL286634A (en) 2021-10-31
CN113891746B (zh) 2025-05-06
US20250320286A1 (en) 2025-10-16
AU2020245031A1 (en) 2021-10-21
PH12021552334A1 (en) 2022-07-04
US20220177560A1 (en) 2022-06-09
CO2021014028A2 (es) 2021-10-29
CR20210492A (es) 2021-11-19
US20200308261A1 (en) 2020-10-01
SG11202110504XA (en) 2021-10-28

Similar Documents

Publication Publication Date Title
EP3891183A4 (fr) Anticorps anti-claudine et leurs utilisations
EP3918323A4 (fr) Anticorps anti-gal3 et leurs utilisations
EP3759143A4 (fr) Anticorps anti-tigit et leurs utilisations
MA55491A (fr) Anticorps anti-pyroglutamate-amyloïde bêta et leurs utilisations
MA52773A (fr) Anticorps anti-cd3 et leurs utilisations
EP3958910A4 (fr) Conjugués anticorps anti-cd45-médicaments et leurs utilisations
EP3898691A4 (fr) Anticorps trem2 et leurs utilisations
EP3849608A4 (fr) Nouveaux anticorps anti-lilrb4 et leurs utilisations
EP3625263A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
MA52949A (fr) Anticorps anti-pd-1 et leurs utilisations
MA54955A (fr) Anticorps anti-claudine 6 et leurs utilisations
EP3790586A4 (fr) Anticorps anti-dll3 et leurs utilisations
EP3962954A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
EP3850012A4 (fr) Anticorps anti-tnfrsf9 et leurs utilisations
EP3908603A4 (fr) Anticorps muc1* antivariables et leurs utilisations
EP3645563A4 (fr) Anticorps anti-fam19a5 et leurs utilisations
EP3755714A4 (fr) Anticorps anti-angiopoïétine-2 et leurs utilisations
EP3894440A4 (fr) Anticorps anti-il-27 et leurs utilisations
MA52235A (fr) Anticorps anti-phf-tau et leurs utilisations
EP4010368A4 (fr) Anticorps anti-nampt et leurs utilisations
EP3768317A4 (fr) Anticorps anti-il-27 et leurs utilisations
MA55613A (fr) Anticorps anti-intégrine et leurs utilisations
EP3755716A4 (fr) Anticorps anti-pd-1 et leurs utilisations
EP4081548A4 (fr) Anticorps monoclonaux anti-sirp? et leurs utilisations
EP3883969A4 (fr) Anticorps anti-pd-1 et leurs utilisations